Premier Biomedical, Inc.
BIEI
$0.0006
$0.000.00%
| 12/31/2019 | 09/30/2019 | 06/30/2019 | 03/31/2019 | 12/31/2018 | |
|---|---|---|---|---|---|
| Revenue | -85.71% | -57.32% | -68.60% | -45.19% | -41.29% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -85.71% | -57.32% | -68.60% | -45.19% | -41.29% |
| Cost of Revenue | -92.06% | -61.36% | -82.18% | -65.57% | 547.22% |
| Gross Profit | 92.75% | -53.85% | 5.26% | -13.95% | -7,745.45% |
| SG&A Expenses | -73.29% | -22.07% | -7.98% | 15.92% | -58.01% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -76.99% | -24.11% | -16.36% | 9.60% | -48.50% |
| Operating Income | 76.84% | 20.54% | 8.42% | -17.77% | 48.62% |
| Income Before Tax | 93.16% | 50.04% | -127.00% | -87.90% | 44.78% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 93.16% | 50.04% | -127.00% | -87.90% | 44.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 93.16% | 50.04% | -127.00% | -87.90% | 44.78% |
| EBIT | 76.84% | 20.54% | 8.42% | -17.77% | 48.62% |
| EBITDA | 76.95% | 21.04% | 8.61% | -17.77% | 48.65% |
| EPS Basic | 99.81% | 93.82% | 33.43% | -95.23% | 74.96% |
| Normalized Basic EPS | 99.85% | 93.89% | 33.49% | -95.21% | 74.61% |
| EPS Diluted | 99.52% | 90.91% | 33.43% | -95.23% | 74.96% |
| Normalized Diluted EPS | 99.85% | 93.89% | 33.49% | -95.19% | 74.61% |
| Average Basic Shares Outstanding | 3,306.56% | 711.15% | 240.90% | 153.57% | 120.52% |
| Average Diluted Shares Outstanding | 3,306.56% | 711.15% | 240.90% | 152.51% | 120.52% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
